Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
BioNTech SE
Hoffmann-La Roche
Amgen
Debiopharm International SA
Hoffmann-La Roche
AstraZeneca
Boehringer Ingelheim
AstraZeneca
AstraZeneca
Bristol-Myers Squibb
Swiss Cancer Institute
Trans Tasman Radiation Oncology Group
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Biotheus Inc.
AstraZeneca
Radiation Therapy Oncology Group
EpicentRx, Inc.
Shandong Cancer Hospital and Institute